Progress in Acute Myeloid Leukemia: Adapting Treatment to Individual Patients

In this online educational program, CCO’s expert faculty explore optimal care for patients with AML, including predictive/prognostic factors to consider in selecting treatment for AML, management of newly diagnosed AML, treatment of relapsed/refractory disease and novel agents that may affect care in the near future.
Jeffrey E. Lancet, MD
Program Director
Jeffrey E. Lancet, MD
Gail J. Roboz, MD
B. Douglas Smith, MD
Roland B. Walter, MD, PhD, MS

ClinicalThought

CPX-351 is beginning to replace traditional 3+7 chemotherapy for secondary or high-risk AML. Learn what you need to know to use it effectively in the clinic.

Jeffrey E. Lancet, MD Released: September 28, 2017

Here are my thoughts on how best to apply the recently approved targeted agents gemtuzumab ozogamicin, midostaurin, and enasidenib to improve outcomes for your patients with acute myeloid leukemia.

B. Douglas Smith, MD Released: October 12, 2017

What are some of the most clinically important AML abstracts to watch for at ASH this year? Read on for a few expert selections.

B. Douglas Smith, MD Released: November 20, 2017

On-Demand Webcast

Watch this on-demand Webcast from the CCO AML satellite symposium at ASH 2017, featuring expert faculty Jeffrey E. Lancet, MD; Gail J. Roboz, MD; B. Douglas Smith, MD; and Roland B. Walter, MD, PhD, MS, as they discuss the most clinically relevant advances in treatment strategies for patients with AML.

Jeffrey E. Lancet, MD
Program Director
Gail J. Roboz, MD B. Douglas Smith, MD Roland B. Walter, MD, PhD, MS
Physicians: maximum of 3.25 AMA PRA Category 1 Credits Released: January 31, 2018 Expiration: January 30, 2019

PDF Summary Resources

Download this guide for a quick overview of phase III multicenter clinical trials in acute myeloid leukemia currently recruiting patients to find a study that may offer your patient an opportunity for the latest individualized treatment in AML.

Released: December 5, 2017

Download this guide for a quick overview of current approaches in the use of molecular analysis to individualize treatment strategies in patients with acute myeloid leukemia.

Released: December 7, 2017

Downloadable Slidesets

In this downloadable slideset, B. Douglas Smith, MD, explores current strategies for diagnosing and treating patients with acute myeloid leukemia based on patient medical history and cytogenetic and molecular markers.

Released: December 12, 2017

In this downloadable slideset, Jeffrey E. Lancet, MD, explores current strategies for treating patients with newly diagnosed acute myeloid leukemia based on patient medical history and cytogenetic and molecular markers.

Released: December 13, 2017

In this downloadable slideset, Gail J. Roboz, MD, explores optimal treatment approaches for patients with relapsed/refractory acute myeloid leukemia.

Released: December 13, 2017

In this downloadable slideset, Roland B. Walter, MD, PhD, MS, examines FLT3, IDH1, and BCL2 inhibitors as well as other promising investigational treatments in clinical trial that may provide therapeutic advances for the management of patients with acute myeloid leukemia.

Released: December 13, 2017
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Supported by educational grants from
Astellas
Daiichi Sankyo
Jazz Pharmaceuticals
Pfizer Inc.

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?